Clinical Trial · NCT03670342

Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer

Overview

Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax \>10) on Ga-68 DOTATATE imaging. Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection. The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE scans. The values gathered will be used as an estimate of the somatostatin receptor density. A patient will be considered to have an overall high somatostatin receptor density if the average SUVmax of all the representative lesions is more than 10.

Sponsor

National Cancer Centre, Singapore

Contacts

Wen Long Nei (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03670342

Drug / Compound

DOTATATE

Isotope(s):

Target(s):

SSTR2

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

Locally advanced NPC or Metastatic NPC or locally recurrent NPC
Histological confirmation of NPC

Exclusion

Pregnancy or breast feeding